European Companies Search Engine
UK funding (£147,145): Synthetic Biology to Improve Antibiotic Production Ukri 1 Jul 2013 UK Research and Innovation, United Kingdom
Overview
Text
Synthetic Biology to Improve Antibiotic Production
| Abstract | Mupirocin is an example of an antibiotic that is the product of a complex synthetic factory found naturally in bacteria. It is currently made industrially using bacteria that have been through successive rounds of selection to find strains that produce more antibiotic during controlled fermentation. It is particularly used against the well known superbug MRSA. The current problems with antibiotic resistant hospital superbugs means that we need more antiobitcs and new antibiotics. Current studies on the bacterial factories that make antibiotics and other products suggest that by changing gene order and improving the signals that switch these genes on it may be possible to increase production. In addition, by combining genes from different pathways one can create new antibiotics or other pharmaceutically active compounds. This project will explore how synthetic biology can be used to build better pathways using our knowledge of how these pathways are programmed. |
| Category | Feasibility Studies |
| Reference | 131174 |
| Status | Closed |
| Funded period start | 01/07/2013 |
| Funded period end | 31/01/2015 |
| Funded value | £147,145.00 |
| Source | https://gtr.ukri.org/projects?ref=131174 |
Participating Organisations
| GLAXOSMITHKLINE PLC |
£147,145.00 |
| UNIVERSITY OF BIRMINGHAM |
The filing refers to a past date, and does not necessarily reflect the current state. The latest known state is available on the following page: GSK plc, London.